987
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?

, &
Pages 669-671 | Published online: 10 Jan 2014

References

  • de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4(12), 686–694 (2007).
  • Goldstein LH, Dolinsky G, Greenberg R et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. 79(10), 696–701 (2007).
  • DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J,. Pediatr. 105(4), 625–628 (1984).
  • Maruyama H, Tada K, Fujiwara T, Ota K, Kageyama M. Utility of maternal 6-thioguanine nucleotide levels in predicting neonatal pancytopenia. AJP Rep. 3(1), 25–28 (2012).
  • van der Woude CJ, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J. Crohns. Colitis. 4(5), 493–510 (2010).
  • Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am. J. Gastroenterol. 102(9), 1947–1954 (2007).
  • Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19(1), 15–22 (2013).
  • Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment. Pharmacol. Ther. 33(6), 707–713 (2011).
  • Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124(1), 9–17 (2003).
  • Coelho J, Beaugerie L, Colombel JF et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60(2), 198–203 (2011).
  • Jharap B, de Boer NK, Stokkers P et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut doi:10.1136/gutjnl-2012-303615 (2013) ( Epub ahead of print).
  • Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34(8), 1081–1085 (1993).
  • de Meij TG, Jharap B, Kneepkens CM, van Bodegraven AA, de Boer NK; Dutch Initiative on Crohn and Colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment. Pharmacol. Ther 38(1), 38–43 (2013).
  • Casanova MJ, Chaparro M, Domenech E et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am. J. Gastroenterol. 108(3), 433–440 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.